MX2019002879A - Compuestos novedosos y usos terapeuticos de los mismos. - Google Patents

Compuestos novedosos y usos terapeuticos de los mismos.

Info

Publication number
MX2019002879A
MX2019002879A MX2019002879A MX2019002879A MX2019002879A MX 2019002879 A MX2019002879 A MX 2019002879A MX 2019002879 A MX2019002879 A MX 2019002879A MX 2019002879 A MX2019002879 A MX 2019002879A MX 2019002879 A MX2019002879 A MX 2019002879A
Authority
MX
Mexico
Prior art keywords
novel compounds
therapeutic uses
compounds
novel
pathogen
Prior art date
Application number
MX2019002879A
Other languages
English (en)
Spanish (es)
Inventor
Westby Michael
Glossop Melanie
Watson Christine
Original Assignee
Centauri Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1615560.8A external-priority patent/GB201615560D0/en
Priority claimed from GBGB1707076.4A external-priority patent/GB201707076D0/en
Application filed by Centauri Therapeutics Ltd filed Critical Centauri Therapeutics Ltd
Publication of MX2019002879A publication Critical patent/MX2019002879A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62Polymyxins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019002879A 2016-09-13 2017-09-13 Compuestos novedosos y usos terapeuticos de los mismos. MX2019002879A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1615560.8A GB201615560D0 (en) 2016-09-13 2016-09-13 Novel compounds and therapeutic uses thereof
GBGB1707076.4A GB201707076D0 (en) 2017-05-04 2017-05-04 Novel compounds and therapeutic uses thereof
PCT/GB2017/052699 WO2018051085A1 (en) 2016-09-13 2017-09-13 Novel compounds and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MX2019002879A true MX2019002879A (es) 2019-09-18

Family

ID=59923474

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002879A MX2019002879A (es) 2016-09-13 2017-09-13 Compuestos novedosos y usos terapeuticos de los mismos.

Country Status (13)

Country Link
US (1) US11014966B2 (https=)
EP (1) EP3512544B1 (https=)
JP (2) JP7185622B2 (https=)
KR (1) KR102544465B1 (https=)
CN (1) CN110022896B (https=)
AU (1) AU2017328896B2 (https=)
BR (1) BR112019004877A2 (https=)
DK (1) DK3512544T3 (https=)
ES (1) ES2854991T3 (https=)
IL (1) IL265269B (https=)
MX (1) MX2019002879A (https=)
WO (1) WO2018051085A1 (https=)
ZA (1) ZA201901422B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201804098D0 (en) * 2018-03-14 2018-04-25 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201904534D0 (en) * 2019-04-01 2019-05-15 Centauri Therapeutics Ltd Novel compounds an therapeutic uses thereof
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof
WO2025236916A1 (en) * 2024-05-16 2025-11-20 Brii Biosciences, Inc. Compositions and methods for treating infections
GB202410052D0 (en) * 2024-07-10 2024-08-21 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
EP1594898A2 (en) * 2003-02-06 2005-11-16 Tripep AB Glycosylated specificity exchangers
CA2517396A1 (en) * 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
BRPI1011269A2 (pt) * 2009-05-05 2016-09-27 Altermune Technologies Llc imunidade quimicamente programável
CA2855916A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
WO2016104647A1 (ja) 2014-12-25 2016-06-30 国立大学法人大阪大学 糖鎖結合ワクチン抗原及び糖鎖導入剤
GB201517859D0 (en) 2015-10-08 2015-11-25 Altermune Ltd Novel compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
US11014966B2 (en) 2021-05-25
EP3512544A1 (en) 2019-07-24
EP3512544B1 (en) 2020-10-28
KR20190064592A (ko) 2019-06-10
AU2017328896B2 (en) 2024-07-25
US20190248838A1 (en) 2019-08-15
JP2022184922A (ja) 2022-12-13
BR112019004877A2 (pt) 2019-06-11
NZ751662A (en) 2025-05-02
JP7185622B2 (ja) 2022-12-07
ES2854991T3 (es) 2021-09-23
KR102544465B1 (ko) 2023-06-19
JP2019526614A (ja) 2019-09-19
CN110022896A (zh) 2019-07-16
WO2018051085A1 (en) 2018-03-22
CA3036405A1 (en) 2018-03-22
CN110022896B (zh) 2023-12-19
IL265269B (en) 2022-04-01
IL265269A (en) 2019-05-30
AU2017328896A1 (en) 2019-04-04
DK3512544T3 (da) 2021-02-01
ZA201901422B (en) 2020-11-25

Similar Documents

Publication Publication Date Title
ZA202311311B (en) Anti-bcma heavy chain-only antibodies
MX2019002879A (es) Compuestos novedosos y usos terapeuticos de los mismos.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
ZA201903985B (en) Anti-bcma heavy chain-only antibodies
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2024014319A (es) Anticuerpos anti-bcma unicamente de cadena pesada
JOP20200110A1 (ar) متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
PH12017501216A1 (en) Binding molecules directed against influenza hemagglutinin and uses thereof
PH12017501522B1 (en) Antibodies to tau and uses thereof
WO2016127179A3 (en) Immunomodulatory agents
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201890572A1 (ru) Биофармацевтические композиции
TN2016000435A1 (en) Novel macrocyclic compounds.
MX2017015279A (es) Exasomas y su uso como vacunas.
IN2014CH00840A (https=)
PH12018500201A1 (en) Enhanced immune response in porcine species
ZA201906580B (en) Novel compounds and therapeutic uses thereof
EA201790321A1 (ru) Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
EA201691465A1 (ru) Средство для лечения сердечно-сосудистых заболеваний
WO2015186139A3 (en) Novel polymorphs of tenofovir disoproxil oxalate and process for preparation of the same
EA201990710A1 (ru) Новые соединения и их терапевтические применения
LV14852A (lv) Triazolilpurīna atvasinājumi kā pretvīrusu preparāti
IN2014MU00666A (https=)